常山药业2025年净利预亏1.9亿元—2.85亿元

Core Viewpoint - Changshan Pharmaceutical (300255) forecasts a net profit attributable to shareholders of between -190 million to -285 million yuan for 2025, representing a year-on-year decline of 14.24% to 23.84% [1] Group 1: Financial Performance - The expected net profit for 2025 is projected to be between -190 million to -285 million yuan, indicating a significant decline compared to the previous year [1] - The decline in profit is attributed to intensified competition in the heparin drug industry and a decrease in revenue from core heparin product series [1] Group 2: Market and Operational Factors - The company cites the impact of centralized procurement policies and fluctuations in raw material prices as contributing factors to maintaining a low gross margin [1] - In response to the centralized procurement policy for its main products, the company is adjusting its sales strategy, optimizing sales team configurations, and reducing distributor levels and terminal maintenance costs [1] - Sales expenses for 2025 are expected to decrease significantly compared to the previous year due to refined management of market expenses [1]